Title of Invention	POLYETHYLENE GLYCOL ALDEHYDE DERIVATIVES
Abstract	Polyethylene glycol aldehyde compounds are provided. Processes of making and using such compounds, as well as chemical intermediates are also provided.

Full Text

Polyethylene glycol aldehyde derivatives The present invention relates to polyethylene glycol aldehydes, and to related methods of making and using such derivatives, such as in the pegylation of polypeptides and other bimolecular. Polyethylene glycol ("PEG") is a linear or branched, neutral polyether, available in a variety of molecular weights. The structure of PEG is H0-(CH2-CH2-0)n-H, where n indicates the number of repeats of the ethylene oxide unit in the PEG. PEG and PEG derivatives have been employed to modify a variety of biomolecules. When attached to such molecules, PEG increases their solubility and increases their size, but has little effect on desirable properties. Advantageously, PEG conjugated biomolecules may exhibit increased retention and delayed metabolism in the body. A variety of PEG derivatives has been developed for such applications. Such PEG derivatives are described, for example, in U.S. Patent 5,252,714; U.S. Patent 5,672,662; U.S. Patent 5,959,265; U.S. Patent 5,990,237; and U.S. Patent 5,340,742. Two general approaches have been used for the functionaiization of PEG; (1) changing the terminal hydroxyl group, through a series of reactions, to a more active functional group and/or (2) reaction of the PEG under controlled conditions with dysfunctional compounds so that one of its functional groups reacts with the PEG polyrner and the other remains active. In most cases, several steps must be conducted to achieve the desired PEG derivatives. The desired PEG derivatives are often produced in low yields and require a complicated purification process to isolate. In addition, PEG derivatives may show nonspecific binding to the biomolecules of interest, which can result in multiple PEGs attached to a single biomolecule and/or PEG attachment at the active site. Multiple PEG attachments may cause difficulty in purification of the pegylated biomolecule. Multiple PEG attachments, and/or pegylation at the active site, can also lead to decreased activity of the biomolecule. It would, therefore, be advantageous to provide improved PEG derivatives suitable for conjugation with a variety of other molecules, including polypeptides and other biomolecules containing an a-amino group. There remains a need to provide PEG derivatives that can be produced in high yield and purity, and that can be conjugated to provide biomolecules having improved performance characteristics. These and other objects of the present invention are described in greater detail below. The compounds of the invention are aldehyde derivatives of polyethylene glycol, having the general formula (I): Z is a side chain of an amino acid, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. The present invention also provides a compound of formula (II): wherein R-i, m, n, and p are defined as above. Another preferred embodiment of the present invention provides a bifunctional polyethylene glycol aldehyde compound of formula (Vlll): (VIII) wherein m, n, and p are is defined as above. The present invention also provides intermediate compounds of formula (IX): wherein Ri, m, n, and p are defined as above. Also provided is an intermediate compound of formula (XI); wherein each m, n, and p is the same or different and is defined as above. The present invention further provides a method of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (IX): wherein Ri, m, n, and p are defined as above. The present invention provides a method of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (XVII): (Vlll) wherein m, n, and p are defined as above. The present invention provides a variety of compounds and chemical! intermediates and methods which may be used in connection with the pegylation of polypeptides and other biomolecules. The present invention provides a new chemical structure for polyethylene glycol aldehydes. The compounds of the invention are aldehyde derivatives of polyethylene glycol, having the general formula (I): Rr(CH2CH20)n-CH2CH2-X-Y-NH-(CH2)p-CHO(l) wherein Ri is a capping group, X is O or NH, Y is selected from the group consisting of Z is a side chain of an amino acid, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. As used herein the Ri "capping group" is any suitable chemical group which, depending upon preference, is generally uncreative or generally reactive with other chemical moieties. The terminal aldehyde group of the above formula permits ready covalent attachment to a chemical moiety of interest, for example, to the Q-amino group of a polypeptide. The Ri capping group is selected to permit or prevent bifunctionality, e.g., covalent attachment to a second chemical moiety of interest. In the case that the capping group is generally uncreative with other chemical moieties Ri is relatively inert. If Ri is relatively inert, then the structure of the resulting polyethylene glycol aldehyde is monofunctionat and therefore covalently bonds with only one chemical moiety of interest. Suitable generally unreactive Ri capping groups include: hydrogen, hydroxyl, lower alkyl, lower alkoxy, lower cycloalkyi, lower alkenyl, lower cycloalkenyl, aryl, and heteroaryl. As used herein, the term "lower alkyl", means a substituted or unsubstituted, straight-chain or branched-chain alkyl group containing from 1 to 7, preferably from 1 to 4, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.butyl, tert.butyl, n-pentyl, n-hexyl, n-heptyl and the like. The term "lower alkoxy" means a lower alkyl group as defined earlier which is bonded via an oxygen atom, with examples of lower alkoxy groups being methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec.butoxy, tert.butoxy, n-phenoxy and the like. The term "lower cycloalkyi" means a substituted or unsubstituted cycloalkyi group containing from 3 to 7, preferably from 4 to 6, carbon atoms, /.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. As used herein, the term "lower alkenyl" means a substituted or unsubstituted, straight-chain or branched-chain alkenyl group containing from 2 to 7, preferably from 2 to 5, carbon atoms, e.g., ethenyl, butenyl, pentenyl, hexenyl and the like. The term "lower cycloalkenyl" means a substituted or unsubstituted, cycloalkenyl group containing from 4 to 7 carbon atoms, e.g., cyclobutenyl, cyclopentenyl, cyclohexenyl and the like. The term "aryl" means a phenyl or naphthyl group which is unsubstituted or optionally mono- or multiply-substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxyl, carboxylic acid, carboxylic ester, nitro, amino, or phenyl, particularly by halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxyl, nitro, amino and phenyl. The term "heteroaryl" means a 5- or 6-membered heteroaromatic group which contains one or more hetero atoms selected from N, S, and O. Preferred generally unreactive Ri capping groups include methoxy, hydroxy!, or benzyloxy. An especially preferred R-i capping group is methoxy. When Ri is methoxy the aldehydes and related compounds are sometimes referred to herein as "mPEG" compounds, wherein the "m" stands for methoxy. If the Ri capping group is generally reactive with other chemical moieties, then R-i is a functional group capable of reacting with some other functional group, such as an amine and/or sulfhydryl in a peptide and/or protein. In such a case, Ri may be a functional group that is capable of reacting readily with electrophilic or nucleophilic groups on other molecules, in contrast to those groups that require strong catalysts or highly impractical reaction conditions in order to react. If Ri is relatively reactive, the polyethylene glycol aldehyde is bifunctionai and may therefore covalently bond with two chemical moieties. Examples of suitable generally reactive Ri capping groups include: halogen, epoxide, maleimide, orthopyridyl disulfide, tosylate, isocyanate, hydrazine hydrate, cyan uric halide, N-succinimidyloxy, sulfo-N-succinimidyloxy, 1-benzotriazolyloxy, 1-imidazolyloxy, p-nitrophenyloxy, and polyethylene glycol aldehyde with aldehyde groups on both ends of the polyethylene glycol aldehyde. And accordingly, the resultant polyethylene glycol aldehyde exhibits binding properties on both ends. It will be appreciated, however, that these bifunctionai compounds need not be perfectly symmetrical, and that the first m, n, and/or p may be the same or different from the second m, n, and/or p in the formula. It is preferred, however, that the compound be symmetrical, meaning that both depicted m's have the same value, both en’s have the same value, and both p's have the same value. In the compounds of the present invention X is O or NH. Preferably, X is O. Further, Y is selected from the group consisting of wherein Z is a side chain of an amino acid. In the present invention, ni is from 1 to 17. In a preferred embodiment, m is from 1 to 14. More preferably m is from 1 to 7, and even more preferably, m is from 1 to 4. Most preferably, m is 1. In the case of a Y group with the general structure: when a single glycine is used as the amino acid. When Z is CH3, then the amino acid is alanine, if Z is CH2OH, the amino acid is serine. Obviously, more complex structures are possible when more and different amino acids are utilized, as can be appreciated from an examination of the various amino acid structures shown below. Preferably, only one amino acid is used. In preferred embodiments, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. The present invention includes, but is not limited to, compounds of formula I which are compounds of formulas ll-Vl as follows: Preferred Ri capping moieties are relatively unreactive, with methoxy, hydroxyl, and benzyloxy preferred. Preferred compounds of the present invention fall within Group A above. Accordingly, the present invention provides a compound of formula (II): (VIll) wherein m, n, and p are defined as above. In a preferred embodiment, Ri is methoxy, m is 1, and n is from 100 to 750. More preferably, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750. The present invention also provides a variety of chemical intermediates which may be converted into the polyethylene glycol aldehyde compounds of the invention described above. These intermediates include compounds of formula (IX): In a preferred embodiment, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. The present invention further provides intermediate compounds of formula (X): In a preferred embodiment, p is 3, Ri is methoxy, m is 1, and n is from '100 to 750; or p is 2, R^ is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. Also provided are intermediate compounds of formula (XI): In preferred embodiments, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. The compounds of the present invention may be produced by any suitable method, using known reagents and methods. However, the present invention provides a specific method of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (IX): wherein Ri, Y, Z, m, n, and p are defined as above. Preferably, the hydrolysis is acid catalyzed. Suitable catalytic acids include: trifiuoroacetic acid, hydrochloric acid, phosphoric acid, sulfuric acid, and nitric acid. Preferably, the acid is trifiuoroacetic acid. In preferred embodiments, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. The polyethylene glycol aldehyde compounds of formula (li) may also be produced by any suitable method. By way of example, however, polyethylene glycol aldehydes of formula (II) may be produced as follows: First, the polyethylene glycol is dried. Second, the polyethylene glycol is reacted with a halogenated derivative of acetic acid. Hydrolyzing the resulting reaction mixture results in a PEG carboxylic acid. Alternatively, the product PEG carboxylic acid may also be derived from direct oxidation of the PEG, after the drying step. Next, the PEG carboxylic acid is then treated with an amine derivative of diethyl acetal to produce a PEG acetal amine, which is reacted with a halogenated carboxylic acid to produce a polyethylene glycol aldehyde of formula. The polyethylene glycol aldehyde product is then collected and purified. The polyethylene glycol aldehyde product may be collected and purified in any suitable manner. By way of example, the polyethylene glycol aldehyde product may be extracted with dichloromethane. The organic layer is dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, PEG aldehyde, is collected by filtration and dried under vacuum. The present invention thus provides a method of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (X): with a compound of formula (XII!): Another method to make PEG acid or PEG carboxylic acid is direct oxidation. In this case, oxidizers such as CrOs or K2Cr207/H2S04, HNO3 in the presence of ammonium van date or June’s reagent (CrOs and H2SO4), may be used. The compound of formula (XII) may be produced by hydrolyzing a compound of formula (XIV): wherein R3 is a branched or unbranched G1-C4 alkyl. The compound of formula (XIV) may be produced by reacting a compound of formula (XV): wherein R2 is halogen. Preferably R2 is bromine or chlorine. Suitable compounds of formula (XVI) include t-butyl bromoacetate, methyl bromoacetate, ethyl bromoacetate, t-butyl chloroacetate, methyl chloroacetate, and ethyl chloroacetate. Other reagents that can be used for this reaction step, i.e., substitutes for formula (XVI) are, e.g., t-butyl bromoacetate, methyl bromoacetate, ethyl bromoacetate, t-butyl chloroacetate, methyl chloroacetate, or ethyl chloroacetate in the presence of potassium t-butoxide, an alkali metal hydride such as sodium hydride or potassium naphtalide. Preferably, the compound of formula (XVI) is t-butyl! bromoacetate. In preferred embodiments, p is 3, Ri is methoxy, ni is 1, and n is from 100 to 750; or p is 2, R-i is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. Compounds of formulas (111) - (VI) (also identified as Groups B-E, respectively) may likewise be made by any suitable means. By way of example, however, the following reaction schemes may be used to produce compounds of formulas (111) - (VI) (Groups B-E). As with the polyethylene glycol aldehydes discussed above, bifunctional polyethylene glycol aldehydes may be produced by any suitable means. The present invention provides a method of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (XVII): wherein m, n, and p are defined as above. The compound of formula (VI) may be produced by reacting a compound of formula (XVHl): with a compound of formula (XIX): The compound of formula (XVIll) may be produced by hydrolyzing a compound of formula (XX): wherein R2 is halogen. The polyethylene glycol aldehyde compositions of the present invention discussed above may be used to derivatize a variety of molecules, including biomolecules, using any suitable methods. The PEG aldehyde compounds of the present invention are N-terminus site-specific for the pagination of peptides and other biomolecules. The PEG aldehydes of the present invention form a conjugate with the N-terminus a-amino group of the biomolecule or protein forming a stable secondary amine linkage between the PEG and the biomolecule or protein. Biomoiecules pegylated with PEG aldehydes of the present invention show reproducibility in the number and location of PEG attachment, resulting in a purification strategy that is less complicated. This site-specific pegylation can result in a conjugate where the pegylation site is far from the site where the biomolecule or the peptide binds to the cell's receptors, which will allow pegylated biomolecules, proteins, or peptides to retain much or ail of their biological activity. The PEG-aldehydes of the present invention can react with any biomolecules that contain an alpha (a) amino group. Depending on the polyethylene glycol aldehyde selected the polyethylene glycol may be covalently bonded to a biomolecule at one end (monofunctional polyethylene glycol aldehyde) or at both ends (bifunctional polyethylene glycol aldehyde). As stated, the polyethylene glycol aldehydes of the present invention may be used for N-terminus site-specific pegylation. The site-specific N-terminal linkage results in pegylated polypeptides which avoid cross-linking and multiple derivatizations of a single polypeptide. To produce this site-specific covalent linkage, any suitable reaction conditions may be used. Generally, the pH of the reaction mixture is sufficiently acidic to activate the a-amino acid of the polypeptide to be pegylated. Typically, the pH is about 5.5 to about 7.4, preferably about 6.5. Accordingly, a method for attaching a polyethylene glycol molecule to a polypeptide comprising: reacting at least one polypeptide of formula (XXll): wherein the polyethylene glycol aldehyde molecule is bonded to the N-terminal amino group of the polypeptide is provided. In preferred embodiments, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 100 to 750. The compounds of formula (XXll) may be any polypeptide, including interferon-alpha, interferon-beta, consensus interferon, erythropoietin (EPO), granulocyte colony stimulating factor (GCSF), granulocyte/macrophage colony stimulating factor (GM-CSF), interleukins (including IL-2, lL-10, and lL-12), and colony stimulating factor. The compounds of formula (XXll) may also be immunoglobulins, such as, IgG, IgE, IgM, IgA, IgD, and subclasses thereof, and fragments thereof. The term "antibody" or " antibody fragments" refer to polyclonal and monoclonal antibodies, an entire immunoglobulin or antibody or any functional fragment of an immunoglobin molecule which binds to the target antigen. Examples of such antibody fragments include Fv (fragment variable), single chain Fv, complementary determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), Fab (fragment antigen binding), F(ab)2', and any combination of those or any other functional group of an immunoglobin peptide capable of binding to a target antigen. As stated, the pegylated compound may be prepared in any desired manner. Conditions, e.g., pH, should be selected which favor the site-specific pegylation of a-amino groups. Generally, polypeptides may be pegylated with polyethylene glycol compounds of the invention by adding the compound of formula (XXII), and the PEG reagent in a molar ratio range of 1:1 to 1:100. The reaction concentration may then placed in a borate, phosphate, or tri buffer at room temperature or 4 degrees Celsius for about .5 to 24 hours at a pH range of 5.5 to 9.0. The molar ratio of PEG reagent to peptide/proteins is generally from 1:1 to 100:1. The concentration of peptide/proteins is generally from 1 to 10 mg/ml. The concentration of buffer is usually 10 to 500 mM. The pegylated compound may be isolated or purified in any desired manner. By way of example, the resultant reaction mixture may be diluted with an equilibration buffer (20m!\/l Tris, pH 7.5) and the resulting mixture is then applied on a Q-Sepharose column. After the mixture is applied on the QA column, it is washed with the equilibration buffer eluted with 75 M NaCl; eluted with 200 mM NaCl; eluted with 1M NaCl; and regenerated with 1M HOAC + 1M NaCl and 0.5 NaOH. By using reverse phase HPLC, it is possible to separate and isolate the N-terminal, monopegylated product from other byproducts in the mixture. Each collected product can then be confirmed by Matrix Assisted Laser Desorption/lionization-Time of Flight IVlass Spectrometry (MALDl-TOF), In a preferred embodiment of the pegylation method of the invention, a polypeptide of formula (XXI!): NH2B (XXII); is reacted with a polyethylene glycol aldehyde molecule of formula (II): Rr(CH2CH20)n-CH2CH2-0-(CH2)m-CO-NH-(CH2)p-CHO (II) wherein Ri, m, n, and p are defined as above; to produce a compound of formula (XXIV); Rr(CH2CH20)n-CH2CH2-0-{CH2)m-CO-NH-(CH2)p-NHB (XXIV) wherein the polyethylene glycol aldehyde molecule is bonded to the N-terminal amino group of the polypeptide. In preferred embodiments, p is 3, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 2, Ri is methoxy, m is 1, and n is from 100 to 750; or p is 1, Ri is methoxy, m is 1, and n is from 1 GO to 750. Additional illustrations of the use of the compounds of the present invention are disclosed in the concurrently filed U.S. Patent Applications entitled "Pegylated T20 Polypeptide," US Serial No. 60/398,195 filed July 24, 2002, and "Pegylated T1249 Polypeptide," US Serial No 60/398,190 filed July 24, 2002, and US Serial No 60/439,213 filed January 10, 2003are incorporated by reference as if recited in full, Further provided, is a method for attaching a polyethylene glycol molecule to a polypeptide comprising: reacting a polypeptide of formula (XXII): NH2B (XXII); with a polyethylene glycol aldehyde molecule of formula (VIII): OHC-(CH2)p-NH-C-(CH2)m-0-CH2CH2-(CH2CH20)n-CH2CH2-0-(CH2)m-C-NH-(CH2)p-CHO wherein each m, n, and p is the same or different and is defined as above; to produce a compound of formula (XXV): O O V-HN-(CH2)p-NH-C-(CH2)ni-0-CH2CH2-(CH2CH20)n-CH2CH2-0-(CH2)rT,-C-NH-(CH2)p-CH2-NHB (XXV) wherein the polyethylene glycol aldehyde molecule is bonded to the N-terminal amino group of the polypeptides. In preferred embodiments, p is 3, m is 1, and n is from 100 to 750; or p is 2, m is 1, and n is from 100 to 750; or p is 1, m is 1, and n is from 100 to 750. The pegylated polypeptides may be used in any desired manner. Suitably, however, they are used to prepare pharmaceutical compositions, by admixture with a pharmaceutically acceptable excipient. Such pharmaceutical compositions may be in unit dosage form. They may be injectable solutions or suspensions, transdermal delivery devices, or any other desired form. The following examples are provided to further illustrate the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way. EXAMPLES Example 1 Preparation of PEG Aldehyde Compounds Five grams of PEG (molecular weight of 1,000 to 60,000 Daltons) in 50 to 100 ml of toluene is azeotropically dried by refluxing for 1 to 3 hours, followed by the removal of 20 to 30mL of toluene. The resulting solution is cooled to room temperature then potassium tert-butoxide (1 to 10 molar excess) in 20-50 ml of absolute tert-butanol and 20-50 ml of toluene is added to the PEG solution. The resulting mixture is then stirred for two hours at room temperature under argon. Tert-butyl bromoacetate (1 to 10 molar excess) is added to the reaction via syringe and the reaction mixture stirred overnight at room temperature under argon gas. Depending on the desired size of the "m" group defined in formula (XVI), tert-butyl bromoacetate can be replaced with another halogenated derivative of acetic acid, e.g., propionic acid, butyric acid, etc. The reaction solution is then condensed by rotary evaporation and the residue precipitated by the addition of diethyl ether. The precipitated product, PEG t-butyl carboxy ester, is filtered off and dried in vacuo, PEG t-butyl carboxy ester (4 g) is then dissolved in 50 to 100 ml of 1N sodium hydroxide and the solution stirred at room temperature overnight. The pH of the mixture is adjusted to 2.5 to 3.0 by addition of 1 to 6N hydrochloric acid, and the mixture extracted with dichloromethane. The organic layer is then dried over sodium sulfate, filtered, concentrated, and precipitated into diethyl ether. The product, PEG-carboxylic acid, is collected by filtration and dried under vacuum. The PEG-carboxylic . acid (3 g) is then dissolved in anhydrous dichloromethane {20-30 ml) followed by the addition of 4-aminobutylraldehyde diethyl acetal (1-5 molar excess), l-hydroxybenzotriazole (1-5 molar excess), and dicyclohexylcarbodiimide (1-5 molar excess). Depending on the desired size of the "p" group defined in formula (XIII), 4-aminobutyraldehyde diethyl acetal can be replaced with another amine derivative of diethyl acetal, e.g., 3-aminopropionaldehyde diethyl acetal or 2-aminoacetalaldehyde diethyl acetal. The resulting mixture is stirred overnight at room temperature under argon gas. The reaction mixture is filtered, concentrated, and precipitated with a mixture of 2-propanol and diethyl ether (1:1). The PEG acetal product is dried in vacuo overnight. The PEG acetal product is then dissolved in 10 - 200 ml of 1 - 90% CF3COOH, and the solution is stirred at room temperature overnight. The pH of the mixture is adjusted to 6.0 by addition of 1 N NaOH solution, and sodium chloride (10 wt %) is then added and the pH of the solution is adjusted to 7.0 by addition of 1 N NaOH. The mixture is then extracted with dichloromethane. The organic layer is dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, PEG aldehyde, is collected by filtration and dried under vacuum. Example 2 Preparation of mPEGinK-butanoaldehvde The following represents a general reaction scheme for preparing mPEGIOk-butanoaldehyde of the invention: First, Carboxymethyl PEG (mPEG) of molecular weight 10,000 daltons (30.0 g, 3 mmol) in 300 mL of toluene was azeotropically dried by refluxing for 2 hours, followed by the removal of 100 ml of toluene. The resulting solution was cooled to room temperature then potassium tert-butoxide (0.68 g, 6 mmol) in 20 ml of absolute tert-butanol and 20 ml of toluene was added to the PEG solution (1). The resulting mixture was stirred for two hours at room temperature under argon. Tert-butyl! bromoacetate (1.00 mL, 6.75 mmol) was added to the reaction via syringe and the reaction was stirred overnight at room temperature under argon. The reaction solution was then condensed by rotary evaporation. The residue was precipitated by addition of diethyl ether. The precipitated product was filtered off and dried/n vactyo. Yield: 28 g. NMR (de-DMSO): 1.40ppm(t, 9H, -CHS); 3.21 ppm (s, -OCH3); 3.50 ppm (s, -O-CH2CH2-O-); 3.96 ppm (s, 2H, -0-CH2-C00-). Next, megaton t-butyl carboxymethyl ester (20 g) was dissolved in 200 mL of 1N sodium hydroxide and the solution was stirred at room temperature overnight (2). The pH of the mixture was adjusted to 2,5 by addition of 6 N hydrochloric acid, and the mixture was extracted with dichloromethane (50 mL, 40 mL, and 30 mL). The organic layer was dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, m-PEGiok-carboxymethyl acid, was collected by filtration and dried under vacuum. Yield: 18 g. NMR (ds-DMSO): 3.21 ppm (s, -OCH3); 3.5 ppm (s, -O-CH2CH2-O-); 3.99 ppm(s, 2H,-0-CH2-COOH). The mPEGiok-carboxymethyl acid (3 g, 0.3 mmol) was dissolved in anhydrous dichloromethane (20 mL) followed by the addition of 4-aminobutyraldehyde diethyl acetal (50 mg, 0.3 mmol), l-hydroxybenzotriazole (40 mg, 0.3 mmol), and dicyclohexylcarbodiimide (80 mg, 0.39 mmol) (3), The mixture was stirred overnight at room temperature under argon. The reaction mixture was filtered, concentrated, and precipitated with a mixture of 2-propanol and diethyl ether (1:1). The product, mPEGiok-butanoacetal, was dried in vacuo overnight. Yield: 2.7 g. NMR (ds-DMSO): 1.07-1.12 ppm (t, 6H, (-0-CH2-CH3)2); 1.46 ppm (m, 4H, -NHCH2CH2CH2-CH-); 3.08-3.11 ppm (q, 2H, -NHCH2CH2CH2-CH-); 3.21 ppm (s, -OCH3); 3,5 ppm (s, -O-CH2CH2-O-); 3.85 ppm (s, 2H, -O-CH2-CO-NH"); 4.44 ppm (t, 1H, -NHCH2CH2CH2-CH-); 7.67 ppm (-NH-). Finally, the mPEGiok-butanoacetal (5 g, 0.5 mmol) was dissolved in 50 mL of 10% CF3COOH and the solution was stirred at room temperature overnight (4). The pH of the mixture was adjusted to 6.0 by addition of 1 N NaOH solution, and sodium chloride (10 wt %) was added and then the pH of the solution was adjusted to 7.0 by addition of 1 N NaOH. The mixture was extracted with dichloromethane. The organic layer was dried over sodium sulfate, filtered, concentrated, and precipitated into diethyl ether. The product, métier butanoaldehyde (5), was collected by filtration and dried under vacuum. Yield: 4.1 g (82%). NMR (dg-DMSO): 3.21 ppm (s, -OCHs); 3.5 ppm (s, -0-CH2CH2-O); 3.85 ppm (s, 2H, -O-CH2-CO-NH-); 7.67 ppm (-NH-); 9.66 ppm (-CHO-). Example 3 Preparation of pegging-acetal aldehyde mPEGiok-acetal aldehyde was prepared by dissolving mPEGiordiethyl acetal (1 g, Mol. Wt. 10,000), which was prepared according to the procedure in Example 1, in 10 ml of 80% trifluoacetic acid (Aldrich, 99+%). The reaction solution was stirred overnight at room temperature under argon gas. IN NaOH was then added dropwise to the reaction solution until a pH of 6.0 was obtained. Next, NaCl (10 wt%) was added to the above solution. The pH was then adjusted to 6.95 ± 0.05 by adding 0.1 N NaOH. The solution was then extracted with methylene chloride. The organic layer was then dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, mPEGior acetal aldehyde, was collected by filtration and dried under vacuum. Yield: 0.85 g (85%). Example 4 Preparation of mPEGipk-propionaldehyde mPEGiok-pfopionaldehyde was prepared by dissolving mPEGiok-propionacetal (2 g, Mol. Wt. 10,000), which was prepared according to the procedure in example 1, in 20 ml of 80% trifluoacetic acid (Aldrich, 99+%)). The reaction solution was stirred overnight at room temperature under argon gas. 1N NaOH was then added dropwise to the reaction solution until a pH of 6.0 was obtained. Next, NaCI (10 wt%>) was added to the above solution. The pH was then adjusted to 6.95 ± 0.05 by adding 1 N NaOH. The solution was then extracted with methylene chloride. The organic layer was then dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, mPEGiok-propionaldehyde, was collected by filtration and dried under vacuum. Yield: 1.8 g (90%). Example 5 Preparation of PEGgok-di-butanoaldehyde PEG20k-di-butanoaldehyde was prepared by dissolving PEG20k-di-butyraidehyde diethyl acetal (3.1 g, Mol. Wt. 20,000), which was prepared according to the procedure in example 1, in 20 ml of 80% trifluoacetic acid (Aldrich, 99+%). The reaction solution was stirred overnight at room temperature under argon gas. 1N NaOH was then added dropwise to the reaction solution until a pH of 6.0 was obtained. Next, NaCI (10 wt%) was added to the above solution. The pH was then adjusted to 6.95 ± 0.05 by adding 0.1 N NaOH. The solution was then extracted with methylene chloride. The organic layer was then dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, Pegboard-butanoaldehyde, was collected by filtration and dried under vacuum. Yield: 2.5 g (81%). Example 6 Preparation of mPEG2Qk-butanoaldehvde mPEG2ok-butanoaldehyde was prepared by dissolving mPEG20k-butyraldehyde diethyl acetal (3.0 g, Mol. Wt. 20,000), which was prepared according to the procedure in Example 1, in 30 ml of 80% trifluoacetic acid (Aldrich, 99+%). The reaction solution was stirred overnight at room temperature under argon gas. IN NaOH was then added dropwise to the reaction solution until a pH of 6.0 was obtained. Next, NaCl (10 wt%) was added to the above solution. The pH was then adjusted to 6.95 ± 0.05 by adding 1 N NaOH. The solution was then extracted with methylene chloride. • The organic layer was then dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, mPEGsok-butanoaldehyde, was collected by filtration and dried under vacuum. Yield: 2.5 g (83.3%). Example 7 Preparation of mPEGgnk-butanoaldehyde mPEG2ok-butanoaldehyde was prepared by dissolving mPEG2ok-butyraldehyde diethyl acetal (14.7 g, Mol. Wt. 20,000), which was prepared according to the procedure in Example 1, in 200 ml of 10% trifluoacetic acid (Aldrich, 99+%). The reaction solution was stirred overnight at room temperature under argon gas. 1N NaOH was then added dropwise to the reaction solution until a pH of 6.0 was obtained. Next, NaCl (10 wt%) was added to the above solution. The pH was then adjusted to 6.95 ± 0.05 by adding 0.1 N NaOH. The solution was then extracted with methylene chloride. The organic layer was then dried over sodium sulfate, filtered, concentrated, and precipitated with diethyl ether. The product, mPEGaok- butanoaldehyde, was collected by filtration and dried under vacuum. Yield: 13.1 g (89%). Claims: 1. A compound of formula (1): Wherein Ri is a capping group, X is O or NH, Y is selected from the group consisting of Z is a side chain of an amino acid, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 2. A compound according to claim 1, wherein Ri is selected from the group consisting of halogen, epoxide, maleimide, orthopyridyl disulfide, tosylate, isocyanate, hydrazine hydrate, cyan uric halide, N-succinimidyloxy, sulfo-N- succinimidyloxy, 1-benzotriazolyloxy, 1-imidazolyloxy, p-nitrophenyloxy, and 3. A compound according to claim 1 having the formula {III): 4. A compound according to claim 1 having the formula (IV): 5. A compound according to claim 1 having the formula (V); 6. A compound according to claim 1 having the formula (VI): 7. A compound of formula (II): wherein Ri is a capping group, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 8. A compound according to claim 7, wherein p is 3. 9. A compound according to claim 7, wherein p is 3, Ri is methoxy, m is 1, and n is from 100 to 750. 10 A compound of formula (VIII): wherein m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. Ri is a capping group, XisOorNH, Y is selected from the group consisting of Z is a side chain of an amino acid, m is from 1 to 17, n is from 10 to 10,000, and ■ p is from 1 to 3. 12. A compound of formula (X): Ri is a capping group, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 13. A compound of formula (XI): wherein m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 14. A process of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (IX): wherein Ri is a capping group, XisOorNH, Y is selected from the group consisting of Z is a side chain of an amino acid, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 15. A process of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (X): Ri is a capping group, m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 16. A process according to claim 15 wherein the compound of formula (X) is produced by reacting a compound of formula (XII): with a compound of formula (XIII): 17. A process according to claim 16 wherein the compound of formula (XI!) is produced by hydrolyzing a compound of formula (XIV): wherein R3 is a branched or unbranched CrC4 alkyl. 18. A process according to claim 17 wherein the compound of formula (XIV) is produced by reacting a compound of formula (XV): wherein R2 is halogen. 19. A process of making a polyethylene glycol aldehyde comprising hydrolyzing a compound of formula (XVII): to produce a polyethylene glycol of formula (VIII): wherein m is from 1 to 17, n is from 10 to 10,000, and p is from 1 to 3. 20. A process according to claim 19 wherein the compound of formula (Vlll) is produced by reacting a compound of formula (XVIIl): with a compound of formula (XIX): 21. A process according to claim 20 wherein the compound of formula (XVIII) is produced by hydrolyzing a compound of formula (XX): wherein R3 is a branched or unbranched CrC4 alkyl. 22. process according to claim 21 wherein the compound of formula (XX) is produced by reacting a compound of formula (XXI): A compound of formula substantially as herein described and exemplified.

Documents:

3125-chenp-2004-abstract.pdf

3125-chenp-2004-assignement.pdf

3125-chenp-2004-claims filed.pdf

3125-chenp-2004-claims granted.pdf

3125-chenp-2004-correspondnece-others.pdf

3125-chenp-2004-correspondnece-po.pdf

3125-chenp-2004-description(complete)filed.pdf

3125-chenp-2004-description(complete)granted.pdf

3125-chenp-2004-form 1.pdf

3125-chenp-2004-form 26.pdf

3125-chenp-2004-form 3.pdf

3125-chenp-2004-form 5.pdf

3125-chenp-2004-other document.pdf

3125-chenp-2004-pct.pdf